This raises the possibility that differences in ADK expression between the heart and breast cancer cells might be exploited by pretreating with AICAr or similar drugs to selectively protect cardiomyocytes against doxorubicin toxicity while enhancing its chemotherapeutic efficacy in tumors. Here, ADK is linked to breast carcinoma.